Wolverine+
Wolverine+ is a research-compound blend of BPC-157, TB-500 and KPV (10 mg each in a 30 mg vial) studied for soft-tissue repair with an added anti-inflammatory component; research protocols typically dose it daily by subcutaneous injection in insulin units off the vial.
Best for
Recovery-focused research where the standard BPC-157 + TB-500 pairing is extended with KPV, an alpha-MSH fragment studied in preclinical models of gut and skin inflammation.
What to expect
Component research and anecdotal reports describe soft-tissue effects over roughly one to several weeks; rigorous human onset data for the blend do not exist.
Pairs with
Commonly run alongside growth-hormone secretagogues such as CJC-1295 + Ipamorelin in recovery stacks; KPV overlaps with gut-focused protocols.
Subcutaneous injection once daily, dosed in units from a 30 mg vial reconstituted with 2 mL of bacteriostatic water. Run in 6–8 week recovery blocks, then a break.
- How often
- Daily
- Route
- Subcutaneous
- Vial & water
- 30 mg (10 each) in 2 mL · 250 mcg each = 5 units on a U-100 syringe
- Cycle
- Run in 6–8 week recovery blocks, then a break.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
Wolverine+ combines the two peptides of the Wolverine blend with a third. BPC-157 is a stable 15-amino-acid gastric-derived peptide characterized preclinically by growth-hormone-receptor upregulation in tendon fibroblasts, nitric-oxide-system interaction and VEGF-linked angiogenesis at the injury site.
TB-500 is a synthetic fragment of thymosin beta-4 that sequesters G-actin to support cell migration and new blood-vessel formation. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied in animal and cell models for NF-κB-linked anti-inflammatory signaling in the gut and skin.
None of the three components is FDA-approved; the blend is handled as a research compound and most evidence comes from animal and in-vitro work.
References3
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (rat model)
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (mouse model)
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (mouse model)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.